Format

Send to

Choose Destination
Blood. 2019 Apr 18;133(16):1715-1719. doi: 10.1182/blood-2018-12-852376. Epub 2019 Feb 22.

Taking a "BiTE out of ALL": blinatumomab approval for MRD-positive ALL.

Author information

1
Section of Hematology/Oncology, Department of Medicine, and University of Chicago Comprehensive Cancer Center, University of Chicago, Chicago, IL.

Abstract

Blinatumomab, a bispecific T-cell engager (BiTE) associated with improved survival in relapsed or refractory acute lymphoblastic leukemia (ALL), was recently approved for treatment of minimal residual disease (MRD). MRD is an important predictor of survival in ALL, and recent studies suggest that achievement of MRD-negativity with blinatumomab improves outcomes in patients with ALL. However, further research is needed to determine how to optimally incorporate blinatumomab, and other novel therapies, into current therapies for ALL.

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center